The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing
Open accessAbstract
SNF'ing out antitumor immunity: Immune checkpoint inhibitors induce durable tumor regressions in some, but not all, cancer patients. Understanding the mechanisms that determine tumor sensitivity to these drugs could potentially expand the number of patients who benefit (see the Perspective by Ghorani and Quezada). Pan et al. discovered that tumor cells in which a specific SWI/SNF chromatin remodeling complex had been experimentally inactivated were more sensitive to T cell–mediated killing. The cells were more responsive to interferon-γ, leading to increased secretion of cytokines that promote antitumor immunity. Miao et al. examined the genomic features of tumors from patients with metastatic renal cell carcinoma who had been treated with immune checkpoint inhibitors. Tumors harboring inactivating mutations in PBRM1 , which encodes a subunit of the same SWI/SNF complex, were more likely to respond to the drugs. Science , this issue p. 770 , p. 801 ; see also p. 745
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Pooled in vivo and in vitro CRISPR-Cas9 based screening have nominated several tumour intrinsic drivers of resistance to immunotherapy 4,8-11 , but therapeutic applications of these findings remain limited.”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [10]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“thus it is surprising that TBK1 has been nominated as a candidate immune evasion gene 4,9-11”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [10]
Experimental — accuracy not yet measuredIn the citing paper
“CRISPR/Cas9 KO screens in murine models or engineered human cell lines testing tumor-T cell interactions identified putative novel mechanisms of immune evasion involving chromatin regulators10, TNFα signaling11, SOX412, PTPN213, and APLNR10, yet their clinical relevance is unclear.”
From Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion (2021) · cites this paper as [12]
In the citing paper
“consistent with prior reports12, induction of CD49f, which encodes an integrin associated with epithelial-to-mesenchymal transition (EMT).”
From Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion (2021) · cites this paper as [12]
In the citing paper
“In previous screens, antigen-specific T cells targeting model tumor associated antigen (TAA), such as OVA, gp100, and NY-ESO-1, were used (Manguso et al., 2017; Pan et al., 2018; Patel et al., 2017).”
From Protein Barcodes Enable High-Dimensional Single-Cell CRISPR Screens (2018) · cites this paper as Pan et al., 2018
In the citing paper
“Several studies have demonstrated that mutations in genes involved in the SWI-SNF chromatin remodeling complex may sensitize human tumors to ICIs and that treatment with an epigenetic modulator can potentiate the ICI-mediated antitumor response through increased production of chemokines responsible for recruiting CD8 + T cells (104-107).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [105]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
Self-citationTrapnell, C., Williams, B. A., Pertea, G., Mortazavi, A., Kwan, G., van Baren, M. J., Salzberg, S. L., Wold, B. J., & Pachter, L. (2010) · Nature Biotechnology · doi:10.1038/nbt.1621 · Cited by 15,556
Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y. C., Laslo, P., Cheng, J. X., Murre, C., Singh, H., & Glass, C. K. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.004 · Cited by 13,382
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., & Greenleaf, W. J. (2013) · Nature Methods · doi:10.1038/nmeth.2688 · Cited by 6,422
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Cited by
Sorted by citations
Items 101–200 of 857
Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance
Lin, H., Kryczek, I., Li, S., Green, M. D., Ali, A., Hamasha, R., Wei, S., Vatan, L., Szeliga, W., Grove, S., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.023 · Cited by 166
The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation
Martin, T. D., Patel, R. S., Cook, D. R., Choi, M. Y., Patil, A., Liang, A. C. T., Li, M. Z., Haigis, K. M., & Elledge, S. J. (2021) · Science · doi:10.1126/science.abg5784 · Cited by 154
Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade
Torrejon, D. Y., Abril-Rodriguez, G., Champhekar, A. S., Tsoi, J., Campbell, K. M., Kalbasi, A., Parisi, G., Zaretsky, J. M., Garcia-Diaz, A., Puig-Saus, C., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1409 · Cited by 146
Alessi, J. V., Ricciuti, B., Spurr, L. F., Gupta, H. V., Li, Y. Y., Glass, C., Nishino, M., Cherniack, A. D., Lindsay, J. R., Sharma, B., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.03.024 · Cited by 156
Long-distance modulation of bystander tumor cells by CD8+ T-cell-secreted IFN-γ
Hoekstra, M. E., Bornes, L., Dijkgraaf, F. E., Philips, D., Pardieck, I. N., Toebes, M., Thommen, D. S., van Rheenen, J., & Schumacher, T. N. (2020) · Nature Cancer · doi:10.1038/s43018-020-0036-4 · Cited by 145
Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response
von Locquenghien, M., Rozalén, C., & Celià-Terrassa, T. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143296 · Cited by 144
Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion
Freeman, A. J., Vervoort, S. J., Ramsbottom, K. M., Kelly, M. J., Michie, J., Pijpers, L., Johnstone, R. W., Kearney, C. J., & Oliaro, J. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.017 · Cited by 140
Wang, G., Chow, R. D.-W., Zhu, L., Bai, Z., Ye, L., Zhang, F., Renauer, P. A., Dong, M. B., Dai, X., Zhang, X., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1448 · Cited by 143
Dysregulation in IFN-γ signaling and response: the barricade to tumor immunotherapy
Han, J., Wu, M., & Liu, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1190333 · Cited by 147
Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response
Garris, C., & Luke, J. J. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1321 · Cited by 146
Ye, B., Fan, J., Xue, L., Yu, Z., Luo, P., Jiang, A., Xie, J., Li, Q., Liang, X., Tan, J., et al. (2025) · iMeta · doi:10.1002/imt2.70011 · Cited by 141
Forde, P. M., Anagnostou, V., Sun, Z., Dahlberg, S. E., Kindler, H. L., Niknafs, N., Purcell, T., Santana-Dávila, R., Dudek, A. Z., Borghaei, H., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01541-0 · Cited by 137
Kalbasi, A. K., Tariveranmoshabad, M., Hakimi, K. N., Kremer, S. V., Campbell, K. M., Funes, J. M., Vega-Crespo, A., Parisi, G., Champhekar, A. S., Nguyen, C., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abb0152 · Cited by 136
Li, J., Yuan, S., Norgard, R. J., Yan, F., Sun, Y. H., Kim, I., Merrell, A. J., Sela, Y., Jiang, Y., Bhanu, N. V., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0519 · Cited by 136
Brenner, E., Schörg, B. F., Ahmetlić, F., Wieder, T., Hilke, F. J., Simon, N., Schroeder, C., Demidov, G. M., Riedel, T., Fehrenbacher, B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14987-6 · Cited by 136
Hodi, F. S., Wolchok, J. D., Schadendorf, D., Larkin, J., Long, G. V., Qian, X., Saci, A., Young, T. C., Srinivasan, S., Chang, H., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0983 · Cited by 138
Mechanisms of Resistance to Immune Checkpoint Blockade
Liu, D., Jenkins, R. W., & Sullivan, R. J. (2018) · American Journal of Clinical Dermatology · doi:10.1007/s40257-018-0389-y · Cited by 135
Lei, T., Wang, Y., Zhang, Y., Yang, Y., Cao, J., Huang, J., Chen, J., Chen, H., Zhang, J., wang, L., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02444-y · Cited by 155
Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma
Jerby‐Arnon, L., Neftel, C., Shore, M. E., Weisman, H. R., Mathewson, N. D., McBride, M. J., Haas, B. J., Izar, B., Volorio, A., Boulay, G., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01212-6 · Cited by 129
Self-citationType I IFN protects cancer cells from CD8+ T cell–mediated cytotoxicity after radiation
Chen, J., Cao, Y., Markelc, B., Kaeppler, J., Vermeer, J. A. F., & Muschel, R. J. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127458 · Cited by 134
MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation
Fang, Y., Wang, L., Wan, C., Sun, Y., der Jeught, K. V., Zhou, Z., Dong, T., So, K. M., Yu, T., Li, Y., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci140837 · Cited by 134
Wu, S., Fukumoto, T., Lin, J., Nacarelli, T., Wang, Y., Ong, D., Liu, H., Fatkhutdinov, N., Zundell, J. A., Karakashev, S. V., et al. (2021) · Nature Cancer · doi:10.1038/s43018-020-00160-x · Cited by 132
Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer
Saux, O. L., Ray-Coquard, I. L., & Labidi‐Galy, S. I. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.08.017 · Cited by 127
Beyond the Barrier: Unraveling the Mechanisms of Immunotherapy Resistance
Bell, H. N., & Zou, W. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101819-024752 · Cited by 143
HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer
Fukumoto, T., Fatkhutdinov, N., Zundell, J. A., Tcyganov, E. N., Nacarelli, T., Karakashev, S. V., Wu, S., Liu, Q., Gabrilovich, D. I., & Zhang, R. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1302 · Cited by 127
Williams, J. B., Li, S., Higgs, E. F., Cabanov, A., Wang, X., Huang, H., & Gajewski, T. F. (2020) · Nature Communications · doi:10.1038/s41467-020-14290-4 · Cited by 128
Jiang, H., Cao, H., Ma, N., Bao, W.-D., Wang, J., Chen, T., Zhang, E., Yuan, Y., Ni, Q., Zhang, F.-K., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1914937117 · Cited by 125
de Andrade, L. F., Kumar, S., Luoma, A., Ito, Y., da Silva, P. H. A., Pan, D., Pyrdol, J. W., Yoon, C. H., & Wucherpfennig, K. W. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0483 · Cited by 131
Self-citationDUX4 Suppresses MHC Class I to Promote Cancer Immune Evasion and Resistance to Checkpoint Blockade
Chew, G.-L., Campbell, A. E., Neef, E. D., Sutliff, N. A., Shadle, S. C., Tapscott, S. J., & Bradley, R. K. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.06.011 · Cited by 132
Structure of human chromatin-remodelling PBAF complex bound to a nucleosome
Yuan, J., Chen, K., Zhang, W., & Chen, Z. (2022) · Nature · doi:10.1038/s41586-022-04658-5 · Cited by 122
SMARCA4: Current status and future perspectives in non-small-cell lung cancer
Tian, Y., Xu, L., Li, X., Li, H., & Zhao, M. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.216022 · Cited by 123
Droplet-based forward genetic screening of astrocyte–microglia cross-talk
Wheeler, M. A., Clark, I. C., Lee, H., Li, Z., Linnerbauer, M., Rone, J. M., Blain, M., Akl, C. F., Piester, G., Giovannoni, F., et al. (2023) · Science · doi:10.1126/science.abq4822 · Cited by 125
ARID1A Mutations Are Associated with Increased Immune Activity in Gastrointestinal Cancer
Li, L., Li, M., Jiang, Z., & Wang, X. (2019) · Cells · doi:10.3390/cells8070678 · Cited by 122
PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer
Chabanon, R. M., Morel, D., Eychenne, T., Daage, L. C., Bajrami, I., Dorvault, N., Garrido, M., Meisenberg, C., Lamb, A. E., Duong-Ngo, C., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0628 · Cited by 120
Chun, H.-J. E., Johann, P. D., Milne, K., Zapatka, M., Büllesbach, A., Ishaque, N., Iskar, M., Erkek, S., Wei, L. L., Tessier‐Cloutier, B., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.013 · Cited by 117
Autophagy protects tumors from T cell–mediated cytotoxicity via inhibition of TNFα-induced apoptosis
Young, T. M., Reyes, C., Pasnikowski, E. M., Castanaro, C., Wong, C. F., Decker, C. E., Chiu, J., Song, H., Wei, Y., Bai, Y., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abb9561 · Cited by 114
Joung, J., Kirchgatterer, P. C., Singh, A., Cho, J. H., Nety, S. P., Larson, R. C., Macrae, R. K., Deasy, R., Tseng, Y., Maus, M. V., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29205-8 · Cited by 119
SOX17 enables immune evasion of early colorectal adenomas and cancers
Goto, N., Westcott, P. M. K., Goto, S., Imada, S., Taylor, M. S., Eng, G. M., Braverman, J., Deshpande, V., Jacks, T., Agudo, J., et al. (2024) · Nature · doi:10.1038/s41586-024-07135-3 · Cited by 122
Henon, C., Blay, J., Massard, C., Mir, O., Bahleda, R., Dumont, S., Postel-Vinay, S. C., Adam, J., Soria, J., & Cesne, A. L. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz160 · Cited by 113
Bai, J., Shi, J., Li, C., Wang, S., Zhang, T., Hua, X., Zhu, B., Koka, H., Wu, H., Song, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21026-5 · Cited by 113
Takada, K., Sugita, S., Murase, K., Kikuchi, T., Oomori, G., Ito, R., Hayasaka, N., Miyanishi, K., Iyama, S., Ikeda, H., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13215 · Cited by 113
Prognostic and Predictive Value of PBRM1 in Clear Cell Renal Cell Carcinoma
Carril-Ajuria, L., Santos, M., Roldán‐Romero, J. M., Rodríguez‐Antona, C., & de Velasco, G. (2019) · Cancers · doi:10.3390/cancers12010016 · Cited by 109
Ostrowski, S. M., & Fisher, D. E. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.08.010 · Cited by 115
Naito, T., Udagawa, H., Umemura, S., Sakai, T., Zenke, Y., Kirita, K., Matsumoto, S., Yoh, K., Niho, S., Tsuboi, M., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.10.009 · Cited by 106
Epigenomic Reprogramming as a Driver of Malignant Glioma
Phillips, R. E., Soshnev, A. A., & Allis, C. D. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.008 · Cited by 111
Epigenetic modifiers as new immunomodulatory therapies in solid tumours
Aspeslagh, S., Morel, D., Soria, J., & Postel-Vinay, S. C. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy050 · Cited by 105
NF-κB and Its Role in Checkpoint Control
Betzler, A. C., Theodoraki, M., Schuler, P. J., Döscher, J., Laban, S. A., Hoffmann, T. K., & Brunner, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113949 · Cited by 106
Pech, M. F., Fong, L. E., Villalta, J. E., Chan, L. J., Kharbanda, S., O’Brien, J. J., McAllister, F. E., Firestone, A. J., Jan, C. H., & Settleman, J. E. (2019) · eLife · doi:10.7554/elife.47362 · Cited by 98
Naito, T., Umemura, S., Nakamura, H., Zenke, Y., Udagawa, H., Kirita, K., Matsumoto, S., Yoh, K., Niho, S., Motoi, N., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13070 · Cited by 98
Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors
Perrier, A., Didelot, A., Laurent‐Puig, P., Blons, H., & Garinet, S. (2020) · Biomolecules · doi:10.3390/biom10071061 · Cited by 100
Epigenetic modifiers: activities in renal cell carcinoma
de Cubas, A. A., & Rathmell, W. K. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0052-7 · Cited by 97
Targeting the NF-κB pathway as a potential regulator of immune checkpoints in cancer immunotherapy
Ebrahimi, N., Abdulwahid, A. R. R., Mansouri, A., Karimi, N., Bostani, R. J., Beiranvand, S., Adelian, S., Khorram, R., Vafadar, R., Hamblin, M. R., et al. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-05098-8 · Cited by 101
Soldi, R., Ghosh, T., Weston, A., Thode, T. G., Drenner, K., Lewis, R., Kaadige, M. R., Srivastava, S., Ampanattu, S. D., del Villar, R. R., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0235705 · Cited by 94
CRISPR screens for functional interrogation of immunity
Shi, H., Doench, J. G., & Chi, H. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00802-4 · Cited by 102
Self-citationSHP-2 and PD-1-SHP-2 signaling regulate myeloid cell differentiation and antitumor responses
Christofides, A., Katopodi, X.-L., Cao, C., Karagkouni, D., Aliazis, K., Yenyuwadee, S., Aksoylar, H., Pal, R., Mahmoud, M. A. A., Strauss, L., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01385-x · Cited by 96
ARID2 is a pomalidomide-dependent CRL4CRBN substrate in multiple myeloma cells
Yamamoto, J., Suwa, T., Murase, Y., Tateno, S., Mizutome, H., Asatsuma‐Okumura, T., Shimizu, N., Kishi, T., Momose, S., Kizaki, M., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0645-3 · Cited by 90
Dubrot, J., Lane-Reticker, S. K., Kessler, E., Ayer, A., Mishra, G., Wolfe, C. H., Zimmer, M. D., Du, P. P., Mahapatra, A., Ockerman, K. M., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.01.001 · Cited by 87
Self-citationTargeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis
Zhou, W., Liu, H., Yuan, Z., Zundell, J. A., Towers, M., Lin, J., Lombardi, S., Nie, H., Murphy, B., Yang, T., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.03.002 · Cited by 99
Retinoblastoma Inactivation Induces a Protumoral Microenvironment via Enhanced CCL2 Secretion
Li, F., Kitajima, S., Kohno, S., Yoshida, A., Tange, S., Sasaki, S., Okada, N., Nishimoto, Y., Muranaka, H., Nagatani, N., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3604 · Cited by 91
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups, Bedognetti, D., Ceccarelli, M., Galluzzi, L., Lu, R. O., Palucka, K., Samayoa, J. A., Spranger, S., Warren, S. E., Wong, K., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0602-4 · Cited by 90
Extracellular Vesicles and Viruses: Two Intertwined Entities
Moulin, C., Crupi, M. J. F., Ilkow, C. S., Bell, J. C., & Boulton, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021036 · Cited by 96
Base editing screens map mutations affecting interferon-γ signaling in cancer
Coelho, M. A., Cooper, S., Strauß, M. E., Karakoç, E., Bhosle, S. G., Gonçalves, E., Picco, G., Burgold, T., Cattaneo, C. M., Veninga, V., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2022.12.009 · Cited by 94
Lizotte, P. H., Hong, R.-L., Luster, T. A., Cavanaugh, M. E., Taus, L. J., Wang, S., Dhaneshwar, A., Mayman, N., Yang, A., Kulkarni, M., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0193 · Cited by 88
The Resistance Mechanisms of Lung Cancer Immunotherapy
Wang, F., Wang, S., & Zhou, Q. H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.568059 · Cited by 90
Mapping genomic and epigenomic evolution in cancer ecosystems
Ushijima, T., Clark, S. J., & Tan, P. B. O. (2021) · Science · doi:10.1126/science.abh1645 · Cited by 89
The mitochondrial Ca2+ uptake regulator, MICU1, is involved in cold stress-induced ferroptosis
Nakamura, T., Ogawa, M., Kojima, K., Takayanagi, S., Ishihara, S., Hattori, K., Naguro, I., & Ichijo, H. (2021) · EMBO Reports · doi:10.15252/embr.202051532 · Cited by 87
Spotlight on TAP and its vital role in antigen presentation and cross-presentation
Mantel, I., Sadiq, B. A., & Blander, J. M. (2021) · Molecular Immunology · doi:10.1016/j.molimm.2021.12.013 · Cited by 87
RETRACTED: MiR-155-5p promotes oral cancer progression by targeting chromatin remodeling gene ARID2
Wu, M. C., Duan, Q., Liu, X., Zhang, P., Fu, Y., Zhang, Z., Liu, L., Cheng, J., & Jiang, H. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109696 · Cited by 86
Self-citationRetractedNguyen, T.-T., Ramsay, L., Ahanfeshar-Adams, M., Lajoie, M., Schadendorf, D., Alain, T., & Watson, I. R. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3365 · Cited by 87
Systematic characterization of mutations altering protein degradation in human cancers
Tokheim, C. J., Wang, X., Timms, R. T., Zhang, B., Mena, E. L., Wang, B., Chen, C., Ge, J., Chu, J., Zhang, W., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.01.020 · Cited by 85
Self-citationHDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer
Zhou, Y., Jin, X., Yu, H., Qin, G.-D., Pan, P., Zhao, J.-Y., Chen, T., Liang, X.-Y., Sun, Y., Wang, B., et al. (2022) · Theranostics · doi:10.7150/thno.69444 · Cited by 78
Integrated chemical and genetic screens unveil FSP1 mechanisms of ferroptosis regulation
Nakamura, T., Mishima, E., Yamada, N., Mourão, A., Trümbach, D., Doll, S. G., Wanninger, J., Lytton, E., Sennhenn, P., da Silva, T. N. X., et al. (2023) · Nature Structural & Molecular Biology · doi:10.1038/s41594-023-01136-y · Cited by 85
KRT17 Promotes T-lymphocyte Infiltration Through the YTHDF2–CXCL10 Axis in Colorectal Cancer
Liang, W., Liu, H., Zeng, Z., Liang, Z., Xie, H., Li, W., Xiong, L., Liu, Z., Chen, M., Jie, H., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0814 · Cited by 82
Context-specific functions of chromatin remodellers in development and disease
Gourisankar, S. P., Krokhotin, A., Wenderski, W., & Crabtree, G. R. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-023-00666-x · Cited by 88
The Role of ARID1A in Tumors: Tumor Initiation or Tumor Suppression?
Xu, S., & Tang, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.745187 · Cited by 87
The evolutionary legacy of immune checkpoint inhibitors
Kaushik, I., Ramachandran, S., Zabel, C., Gaikwad, S., & Srivastava, S. K. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.020 · Cited by 79
The diversity of CD8+ T cell dysfunction in cancer and viral infection
Galluzzi, L., Smith, K. N., Liston, A., & Garg, A. D. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01161-6 · Cited by 94
Fouassier, L., Marzioni, M., Afonso, M. B., Dooley, S., Gaston, K., Giannelli, G., Rodrigues, C. M. P., Lozano, E., Mancarella, S., Segatto, O., et al. (2019) · Liver International · doi:10.1111/liv.14102 · Cited by 79
Friedman, C. F., Snyder, A., Zhou, Q. C., Carducci, M. A., de Meritens, A. B., Corr, B. R., Fu, S., Hollmann, T. J., Iasonos, A. E., Konner, J. A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001126 · Cited by 78
Yang, Z., Liu, X., Zhu, J., Chai, Y., Cong, B., Li, B., Gao, W.-F., Hu, Y., Wen, M., Liu, Y., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.11.008 · Cited by 83
Self-citationApplication of CRISPR/Cas9 gene editing technique in the study of cancer treatment
Jiang, C., Meng, L., Yang, B., & Luo, X. (2019) · Clinical Genetics · doi:10.1111/cge.13589 · Cited by 83
Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors
Alaiwi, S. A., Nassar, A. H., Xie, W., Bakouny, Z., Berchuck, J. E., Braun, D. A., Baca, S. C., Nuzzo, P. V., Flippot, R., Mouhieddine, T. H., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0866 · Cited by 80
Self-citationBao, R., Stapor, D. C., & Luke, J. J. (2020) · Genome Medicine · doi:10.1186/s13073-020-00787-6 · Cited by 80
Cui, Y., Li, J., Zhang, P., Yin, D., Wang, Z., Dai, J., Wang, W. T., Zhang, E., & Guo, R. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02711-3 · Cited by 82
VDAC2 loss elicits tumour destruction and inflammation for cancer therapy
Yuan, S., Sun, R., Shi, H., Chapman, N. M., Hu, H., Guy, C. S., Rankin, S. L., Anil, K. C., Palacios, G., Meng, X., et al. (2025) · Nature · doi:10.1038/s41586-025-08732-6 · Cited by 82
Integrative multi-omics approaches to explore immune cell functions: Challenges and opportunities
Wang, X., Dian, F., Yang, Y., Gimple, R. C., & Zhou, S. (2023) · iScience · doi:10.1016/j.isci.2023.106359 · Cited by 87
Bihr, S., Ohashi, R., Moore, A. L., Rüschoff, J. H., Beisel, C., Hermanns, T., Mischo, A., Corrò, C., Beyer, J., Beerenwinkel, N., et al. (2019) · Neoplasia · doi:10.1016/j.neo.2018.12.006 · Cited by 82
Wu, C.-Y., Lau, B. T., Kim, H. S., Sathe, A., Grimes, S. M., Ji, H. P., & Zhang, N. R. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-00911-w · Cited by 75
Benham-Pyle, B. W., Brewster, C. E., Kent, A. M., Mann, F. G., Chen, S., Scott, A. R., Box, A., & Alvarado, A. S. (2021) · Nature Cell Biology · doi:10.1038/s41556-021-00734-6 · Cited by 71
Wu, C.-C., Wang, Y., Livingston, J. A., Zhang, J., & Futreal, P. A. (2022) · Nature Communications · doi:10.1038/s41467-021-27651-4 · Cited by 80
Zhao, L., Liu, P., Mao, M., Zhang, S., Bigenwald, C., Dutertre, C., Lehmann, C. H. K., Pan, H., Paulhan, N., Amon, L., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1338 · Cited by 77
Hagiwara, M., Fushimi, A., Yamashita, N., Bhattacharya, A., Rajabi, H. N., Long, M. D., Yasumizu, Y., Oya, M., Liu, S., & Kufe, D. W. (2021) · Oncogene · doi:10.1038/s41388-021-01899-y · Cited by 73
Bu, M. T., Chandrasekhar, P., Ding, L., & Hugo, W. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108211 · Cited by 72
Chow, R. D.-W., Michaels, T., Bellone, S., Hartwich, T. M. P., Bonazzoli, E., Iwasaki, A., Song, E., & Santin, A. D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0686 · Cited by 78
Molecular Pathways in Melanomagenesis: What We Learned from Next-Generation Sequencing Approaches
(IMI), F. T. I. M. I., Palmieri, G., Colombino, M., Casula, M., Manca, A., Mandalà, M., & Cossu, A. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0733-7 · Cited by 74
The “ART” of Epigenetics in Melanoma: From histone “Alterations, to Resistance and Therapies”
Strub, T., Ballotti, R., & Bertolotto, C. (2020) · Theranostics · doi:10.7150/thno.36218 · Cited by 73
Sheng, W., Liu, Y., Chakraborty, D., Debo, B. M., & Shi, Y. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0017 · Cited by 71
SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer
Botta, G. P., Kato, S., Patel, H., Fanta, P. T., Lee, S., Okamura, R., & Kurzrock, R. (2021) · JCI Insight · doi:10.1172/jci.insight.150453 · Cited by 71
Ballesteros, P. Á., Chamorro, J., Román, M. S., Pozas, J., Santos, V. G. D., Granados, Á. R., Grande, E., Alonso‐Gordoa, T., & Molina‐Cerrillo, J. (2021) · Cancers · doi:10.3390/cancers13235981 · Cited by 74
Metadata
- Authors
- Pan, D., Kobayashi, A., Jiang, P., Ferrari de Andrade, L., Tay, R. E., Luoma, A. M., Tsoucas, D., Qiu, X., Lim, K., Rao, P., Long, H. W., Yuan, G.-C., Doench, J., Brown, M., Liu, X. S., & Wucherpfennig, K. W.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Astellas Pharma (Japan) (JP)
- Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
- Broad Institute (US)
- Harvard University (US)
- Corresponding author
- Pan, Deng
- Kobayashi, Aya
- Jiang, Peng
- Liu, X. Shirley
- Wucherpfennig, Kai W.
- ORCID
- Venue
- Science
- Published
- 2018-02-16
- Volume
- 359
- Issue
- 6377
- Pages
- 770-775
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC5953516
- OpenAlex
- W2782124401
- Cited by
- 852
- References
- 51
- Citations by year
- 2026: 39 · 2025: 96 · 2024: 92 · 2023: 107 · 2022: 123 · 2021: 117 · 2020: 143 · 2019: 86 · 2018: 47
- FWCI
- 36.93
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (R01CA173750)
- Astellas Pharma
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- SWI/SNF complex, PBRM1, immune checkpoint inhibitors, T cell-mediated killing, antitumor immunity, interferon-gamma, renal cell carcinoma, chromatin regulation
- MeSH terms
- CRISPR-Associated Protein 9, Bromodomain Containing Proteins, Animals, Bacterial Proteins, Chromosomal Proteins, Non-Histone, Cytotoxicity, Immunologic, DNA-Binding Proteins, Endonucleases, Genetic Testing, Humans, Immunotherapy, Interferon-gamma, Melanoma, Experimental, Skin Neoplasms, T-Lymphocytes, Cytotoxic, Transcription Factors, HMGB Proteins, Cell Line, Tumor, Mice, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
